SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-24-012639
Filing Date
2024-04-22
Accepted
2024-04-22 08:02:00
Documents
16
Period of Report
2024-04-22
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbla20240421_8k.htm   iXBRL 8-K 28107
2 EXHIBIT 99.1 ex_657494.htm EX-99.1 17143
7 image01.jpg GRAPHIC 16573
  Complete submission text file 0001437749-24-012639.txt   206900

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pbla-20240422.xsd EX-101.SCH 3409
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbla-20240422_def.xml EX-101.DEF 11424
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbla-20240422_lab.xml EX-101.LAB 15310
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbla-20240422_pre.xml EX-101.PRE 11584
19 EXTRACTED XBRL INSTANCE DOCUMENT pbla20240421_8k_htm.xml XML 2840
Mailing Address 712 VISTA BLVD #305 WACONIA MN 55387
Business Address 712 VISTA BLVD #305 WACONIA MN 55387 9524791196
Panbela Therapeutics, Inc. (Filer) CIK: 0001029125 (see all company filings)

IRS No.: 870543922 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39468 | Film No.: 24859541
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)